Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Next Generation Protein Therapeutics & Bioconjugates conference in San Francisco, California on 19 June 2019.
Dr Basran’s presentation, ‘Affimer Therapeutics: A Novel Human Scaffold for the Generation of Bi-specific Molecules’, will give an overview of the benefits of using Affimer technology to generate bispecific drug molecules.
Bispecific therapy – single molecules that engage with two drug targets simultaneously – is a major area of focus in large pharma immuno-oncology programmes. Avacta has highlighted bispecifics as a key element of its therapeutic pipeline strategy, alongside the development of its novel tumour microenvironment activated drug conjugates.
Dr Basran’s presentation will highlight the stability, solubility and ease of manufacturing functional Affimer bispecifics incorporating Avacta’s proprietary serum half-life extension technology (Affimer XTTM), as well as PD-L1 and LAG-3 Affimer inhibitors.